Effectiveness of Ruxolitinib was also seen in primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma [104], BCP-ALL [14] and ALCL [105], in which the JAK/STAT pathway played a vital role. The gene discussed is SOAT1; the disease is acute lymphoblastic leukemia.